Expanded Access Programme of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-negative Chronic Hepatitis B

Trial Profile

Expanded Access Programme of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-negative Chronic Hepatitis B

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Expanded access; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 13 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top